StockData
Evofem Biosciences, Inc. logo

Evofem Biosciences, Inc. (EVFM) stock

EVFMOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$0.01−0.00 (-10.00%)

Close on Oct 19, 2026Market cap $865.23KP/E –Yield –

Earnings

Evofem Biosciences's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 10, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
$4.60M
-8.0% on a year earlier
EPS, Q3 FY2026
$0.00
-$0.01 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Evofem Biosciences's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 10, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 13, 2026after the close$4.60M-8.0%$0.00Release
Q1 FY2026ended Mar 31, 2026May 18, 2026before the open$900.00K+12.5%-$0.04Release
Q4 FY2025ended Dec 31, 2025Mar 11, 2026after the close$9.60M+35.2%$0.00Release
Q3 FY2025ended Sep 30, 2025Nov 13, 2025after the close$5.00M+11.1%-$0.01Release
Q2 FY2025ended Jun 30, 2025Aug 14, 2025before the open$4.80M+14.3%-$0.02Release
Q1 FY2025ended Mar 31, 2025May 15, 2025before the open$800.00K–$0.00Release
Q4 FY2024ended Dec 31, 2024Mar 24, 2025before the open$7.10M–-$0.03Release
Q3 FY2024ended Sep 30, 2024Nov 14, 2024after the close$4.50M–-$0.02Release
Q2 FY2024ended Jun 30, 2024Aug 14, 2024before the open$4.20M–$0.00Release
Q1 FY2024ended Mar 31, 2024May 15, 2024before the open–––Release
Q4 FY2023ended Dec 31, 2023Mar 27, 2024before the open–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Evofem Biosciences has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Evofem Biosciences puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Evofem Biosciences filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Update
  3. Results
  4. Update
  5. Results
  6. Results
  7. Update
  8. Results
  9. Update
  10. Results
  11. Update
  12. Results
  13. Results
  14. Results
  15. Results

See a number that looks wrong?